BEIJING-ZHENWEI
The 5th Beijing International Import Food Expo 2016 (cipfe 2016) will take place on 6th -8th May, 2016 at Beijing Exhibition Center. With an exhibition area of 20,000m2 , cipfe 2016 will present 10 pavilions covering leisure food (chocolates, candies, nuts and etc), coffee and tea, beverage, organic food, wines and beers, dairy, oil, meat, etc. Over 600 international food enterprises from more than 30 countries and regions are expected to attend the exhibition, including US, Italy, Spain, Australia, Thailand, South Korea and Malaysia.
Under the theme of “Share the Global Taste”, the organizers of the event, China Chamber of International Commerce (CCOIC) and Zhenwei Exhibition Group, will provide the biggest national-level imported food trade platform for over 32,000 visitors, including import-export traders, food distributors, supermarkets, hotels, restaurants, top clubs and other related industry sectors. As one of the highlights in the exhibition, numerous buyers will also seek potential consumers and enlarge their business cooperation in Asian market.
In order to attract the most influential targeted visitors during the three-day event, the diamond buyers invitation group of cipfe 2016 will identify valuable buyers and establish and maintain contact with them, so that the exhibitors can learn the latest ideas and thoughts of the attendees. Meanwhile, some seminars such as Products Promotion Seminar, Oversea Products Purchasing Seminar and World Delicacy Tasting Seminar will be concurrently held during the exhibition.
Besides, over 100 mainstream media like People’s Daily, CCTV, Xinhua, China Daily, Beijing TV Station, sina.com.cn, ifeng.com, sohu.com, China Taiwan and Asia Food will attend the event and offer the latest industry information and investment opportunities for visitors and buyers worldwide. Furthermore, Business Recruitment Agency Conference, World Food Tasting Conference and Networking of Shop, Supermarket and E-commerce will also create great chances for both traders and buyers to learn the development trend of the food industry and make long-term win-win collaborations.
More information about cipfe 2016, please visit: www.cipfe.com .
About cipfe
Beijing International Import Food Expo (cipfe) is the only one National-level import food expo in Beijing. The CCOIC and Zhenwei will build a famous Brand Exhibition Project, and make full use of the 200,000 professional database, which include the international buyers in China, Food agencies, Supermarket, High-end club etc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005027/en/
Contact:
Beijing Zhenwei Exhibition Co., Ltd.
Margaret Duan or Cassidy Liu,
+8613910314389, +86-10-58236512
cipfe@zhenweiexpo.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom